CN115010958A - 一种用于促进伤口愈合的水凝胶及其制备方法和应用 - Google Patents
一种用于促进伤口愈合的水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN115010958A CN115010958A CN202210517870.0A CN202210517870A CN115010958A CN 115010958 A CN115010958 A CN 115010958A CN 202210517870 A CN202210517870 A CN 202210517870A CN 115010958 A CN115010958 A CN 115010958A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- codonopsis pilosula
- polysaccharide
- acetylated
- pilosula polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 104
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000029663 wound healing Effects 0.000 title claims abstract description 11
- 230000001737 promoting effect Effects 0.000 title claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 65
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 65
- 239000005017 polysaccharide Substances 0.000 claims abstract description 65
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 50
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960003638 dopamine Drugs 0.000 claims abstract description 19
- 230000021736 acetylation Effects 0.000 claims abstract description 8
- 238000006640 acetylation reaction Methods 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000003431 cross linking reagent Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic acid anhydride Natural products CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- XNIJPPBKASPAIZ-ZYAQMDEOSA-N Genipinic acid Natural products O=C(OC)[C@H](C(=O)O)[C@H]1C=2[C@@H](O)OCC=2CC1 XNIJPPBKASPAIZ-ZYAQMDEOSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 241000756943 Codonopsis Species 0.000 claims 3
- 230000000397 acetylating effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 3
- 230000006944 antioxidant bioactivity Effects 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- -1 phytosterols Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
- C08K5/092—Polycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/15—Heterocyclic compounds having oxygen in the ring
- C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
- C08K5/1545—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/17—Amines; Quaternary ammonium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于生物医用材料领域，具体涉及一种用于促进伤口愈合的水凝胶及其制备方法和应用。一种用于促进伤口愈合的水凝胶，该水凝胶的原料组分包含改性党参多糖。本发明的水凝胶通过乙酰化改性修饰党参多糖，又与多巴胺进行共混接枝交联，结果发现该水凝胶不仅具有较高的抗氧化生物活性，还具有较好的黏附性，并在后续测试该水凝胶的抗菌性能实验中发现，相比未加多巴胺的水凝胶，本发明水凝胶的抗菌性大大提升了。
Description
技术领域
本发明属于生物医用材料领域，具体涉及一种用于促进伤口愈合的水凝胶及其制备方法和应用。
背景技术
人体最常见的皮肤损伤修复过程是一个动态过程，包括4个阶段，其中第2阶段开始于蛋白水解酶与促炎因子从侵入的免疫细胞释放到伤口区域，产生炎症免疫反应，这类炎性细胞产生活性氧促进伤口修复进程，但过高浓度的ROS水平可能通过增加氧化应激与脂质过氧化甚至造成严重的细胞损伤而阻止伤口愈合。在这一阶段，所有的异物与组织碎片都被嗜中性粒细胞与巨噬细胞从伤口床清除，此外细胞因子和相应酶的释放刺激成纤维细胞和成肌细胞的生长，在此过程中伤口渗出液为愈合过程提供了必需的水分。
创面敷料能遮盖和保护伤口，促进外伤、烧伤、糖尿病足和术后切口的伤口愈合。理想的伤口敷料可以提供湿润的环境、防止继发性感染、清除多余的组织渗液、促进创面附近组织再生、提高伤口愈合质量并减少瘢痕的产生。水凝胶敷料能够提供湿润的创面环境，防止二次感染，促进坏死创面和肉芽创面的自溶清创，提高创面愈合效率，是一种较为理想的创面敷料。与人工合成聚合物水凝胶相比，天然生物聚合物水凝胶（如多糖水凝胶和多肽水凝胶等）具有生物相容性良好、可降解性、生物特异性、不会引起免疫和毒性反应、降解时间可控、降解产物无毒、无免疫原性且最终代谢产物可以排出体外等优点。自2002年受贻贝启发的多巴（DOPA）改性水凝胶的制备被报道以来，利用DOPA结构单元修饰水凝胶备受关注。DOPA的关键结构单元是邻苯二酚结构，它能够与各种无机/有机/金属表面形成强共价键和非共价键，从而大大提升水凝胶的黏附性与力学性能。同时，大量研究表明，邻苯二酚官能化水凝胶组织黏附性极佳，且抗氧化活性较强。
研究表明，党参含有多糖类、植物甾醇类、萜类、生物碱类、苯丙素苷类等多种化学成分，其中多糖类所占比例最大，是党参具有增强机体免疫力、抗衰老和降血糖等多种作用的主要活性成分。已有研究表明党参多糖（CPP）对超氧阴离子自由基具有清除作用，有一定的抗氧化活性且对机体部分损伤有保护作用。目前，党参多糖的生物活性研究大多局限于其对免疫***功能的调节方面，这在某种程度上阻碍了药材党参的相关新药资源开发，致使药材党参的附加值不高，制约了党参种植及相关产业的发展。
天然多糖的生物活性和理化性质与其结构密切相关。为了更好地发挥多糖的功效，使其有着更为广泛的应用，研究人员常常对多糖分子进行修饰或改性。多糖的改性可以提高多糖的生物活性和吸收效率，并赋予其新的功效。同时多糖改性技术也能为一些因为结构性质而无法发挥其活性或是无法投入工业化生产的多糖提供新的利用途径。但是，许多改性方法还存在着缺陷，如改性成本高昂、改性条件苛刻、改性工艺危险、改性副产物阻碍改性进行或造成污染等，这些极大地限制了多糖改性技术的大规模应用。
发明内容
为了解决上述的技术问题，同时为党参多糖的进一步***研究和开发奠定基础，填补现有医用材料中的空白，本发明提供了一种新型天然的水凝胶生物材料。本申请人通过对党参多糖进行乙酰化修饰，以期增大党参多糖的溶解度，从而增强其生物活性，又为进一步提高水凝胶的粘附性和力学性能，将改性后的多糖与多巴胺进行共混接枝交联。对本发明的水凝胶进行性能实验评价，结果发现该水凝胶不仅具有较好的黏附性，还具有较高的抗氧化生物活性，应用于皮肤伤口敷料中可以加快伤口愈合的速度和质量。另外，本申请人在测试该水凝胶的抗菌性能实验中还发现，相比未加多巴胺的水凝胶，本发明水凝胶的抗菌性大大提升了。
为了实现上述的发明目的，本发明采用了以下的技术方案：
一种用于促进伤口愈合的水凝胶，该水凝胶的原料组分包含改性党参多糖。
作为优选，所述改性党参多糖是乙酰化党参多糖。乙酰基能改变多糖分子的定向性和横次序，从而改变多糖的物理性质，乙酰基的引入使分子的伸展变化，最终可导致多糖羧基基团的暴露，增加在水中的溶解性。
作为优选，所述乙酰化党参多糖采用的乙酰化改性剂为冰醋酸或乙酸酐中的一种。
作为优选，所述水凝胶的原料组分还包含多巴胺和交联剂。水凝胶可以通过物理或者化学的方法形成，物理交联的水凝胶往往具有较好的生物相容性但是机械性能较差，化学交联形成的水凝胶则比较稳定，但化学交联剂的引入往往会导致细胞相容性较差从而限制其应用。
作为优选，所述交联剂为京尼平和柠檬酸中的一种或多种组合。京尼平和柠檬酸属于天然生物交联剂，可以与含有氨基的聚合物交联形成生物材料，其毒性远远低于戊二醛和其他化学交联剂。
进一步，本发明提供了所述的水凝胶的制备方法，所述方法包括以下步骤：
1）乙酰化党参多糖的制备：将党参多糖用去离子水充分溶解，加入乙酰化改性试剂，用NaOH溶液控制体系pH8.0-10.0，搅拌反应1-2h，用HCl溶液调节pH至中性，终止反应后透析36-48h，透析液旋转蒸发仪中减压浓缩后加入无水乙醇，4℃醇沉24-48h，冷冻干燥后得乙酰化党参多糖。
2）将步骤1）得到的乙酰化党参多糖加入去离子水中，加热搅拌至溶解，得到乙酰化党参多糖水溶液，加入交联剂水溶液混合，室温下搅拌均匀后静置，然后加入多巴胺水溶液，加热搅拌均匀后静置得到水凝胶。
作为优选，所述乙酰化党参多糖水溶液的质量浓度为5wt%-10wt%。
作为优选，所述多巴胺水溶液的质量浓度为1wt%-8wt%。
作为优选，所述交联剂水溶液的质量浓度为1wt%-2wt%。
进一步，本发明提供了所述的水凝胶和所述的制备方法在医用敷料中的应用。
采用本技术方案的有益效果是：本发明水凝胶制备采用的原料组分均为自然界中本身存在的天然物质，对皮肤和身体无毒且无刺激性，具有良好的生物可降解性。本发明通过多糖改性技术对党参多糖进行乙酰化修饰，提高了其清除自由基的能力，结合多巴胺混合接枝交联后，具有良好的机械性能和生物组织黏附性，同时反应中采用的是天然交联剂，与常用的化学交联剂戊二醛相比，具有生物相容性好的优势。此外，由于伤口修复过程往往伴随细菌感染，因此对本发明水凝胶的抗菌性能进行了测试，结果发现该水凝胶的抗菌性能有较大的提升，最终得到一种具有良好的抗氧化性能和一定的生物组织黏附性，以及抗菌性能优异的新型水凝胶材料，在生物医药材料领域中具有较好的应用前景。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清查、完整的描述，进而进一步解释发明。显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部实施例。给予本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
主要实验试剂和材料：
党参多糖、多巴胺、京尼平、柠檬酸和戊二醛均购自市售产品。大肠杆菌和金黄色葡萄球菌购自国家微生物保藏中心。
实施例1水凝胶的配方和制备方法
| 原料组分 | 水凝胶1 | 水凝胶2 | 水凝胶3 | 水凝胶4 | 水凝胶5 | 水凝胶6 | 水凝胶7 | 水凝胶8 |
| 党参多糖 | 7wt% | - | - | - | - | - | - | 7wt% |
| 乙酰化党参多糖 | - | 7wt% | 7wt% | 7wt% | 7wt% | 7wt% | 7wt% | - |
| 多巴胺 | - | - | - | - | - | 1wt% | 6wt% | 6wt% |
| 京尼平 | - | - | 1wt% | - | 0.5wt% | 0.5wt% | 0.5wt% | 0.5wt% |
| 柠檬酸 | - | - | - | 1wt% | 0.5wt% | 0.5wt% | 0.5wt% | 0.5wt% |
| 戊二醛 | 1wt% | 1wt% | - | - | - | - | - | - |
注：“-”表示不含该组分。
本发明水凝胶的制备方法：1）乙酰化党参多糖的制备：将党参多糖用去离子水充分溶解，加入乙酰化改性试剂，用NaOH溶液控制体系pH8.0-10.0，搅拌反应1-2h，用HCl溶液调节pH至中性，终止反应后透析36-48h，透析液旋转蒸发仪中减压浓缩后加入无水乙醇，4℃醇沉24-48h，冷冻干燥后得乙酰化党参多糖。2）将步骤1）得到的乙酰化党参多糖加入去离子水中，加热搅拌至溶解，得到乙酰化党参多糖水溶液，加入交联剂水溶液混合，室温下搅拌均匀后静置，然后加入多巴胺水溶液，加热搅拌均匀后静置得到水凝胶。
实施例中其余水凝胶的制备除配方组分和含量不同，其他方法步骤基本一致。
实施例2水凝胶的体外抗氧化活性测定
对DPPH自由基清除能力的测定：取水凝胶样品用0.05M/L醋酸溶液溶解，分别取2.0mL的样品溶液，加入2.5mL0.1mmol/L的DPPH95%乙醇溶液，充分混匀，室温下震荡，完全反应。避光反应30min，于517nm处测其吸光度。每个样品重复三次。以蒸馏水代替水凝胶样液作空白对照，按下式计算清除率：DPPH自由基清除率/%=（A 2-A 1）/A 2×100。式中，A 1为实验组吸光度；A 2为空白组吸光度。结果如表1所示。从表1数据可以发现，相比未经修饰的党参多糖，采用乙酰化党参多糖制备的水凝胶具有较高的DPPH自由基清除率，说明乙酰化修饰改性党参多糖能够一定程度提高其生物抗氧化活性，且其中采用天然交联剂制备得到的水凝胶抗氧化活性高于采用戊二醛作交联剂得到的水凝胶，DPPH自由基清除率达到了82%以上。
表1
| 样品 | 水凝胶1 | 水凝胶2 | 水凝胶3 | 水凝胶4 | 水凝胶5 | 水凝胶6 | 水凝胶7 | 水凝胶8 |
| DPPH自由基清除率（%） | 51.05 | 73.77 | 81.20 | 82.68 | 82.51 | 82.04 | 81.43 | 50.37 |
实施例3水凝胶的粘性性能表征
采用AG-Xplus万能材料试验机测试的生物粘性。将片状生物粘性水凝胶切成长20mm×宽10mm×厚1mm的试样，与人体手背皮肤在100g的压力下接触1min达到粘接，随后夹住水凝胶没有被粘接的部分，向上拉伸将其从人体表皮处剥离，得到水凝胶生物粘性的剥离应力-应变曲线，取剥离时的平均应力作为水凝胶的粘接强度。从表2的实验数据可以发现，相比未添加多巴胺的水凝胶，采用多巴胺制备的水凝胶具有较高的粘性，说明通过多巴胺的共混接枝交联能够一定程度提升凝胶的生物组织黏附性。
表2
| 样品 | 水凝胶1 | 水凝胶2 | 水凝胶3 | 水凝胶4 | 水凝胶5 | 水凝胶6 | 水凝胶7 | 水凝胶8 |
| 粘接强度（kPa） | 5.29 | 6.03 | 6.15 | 6.07 | 6.10 | 7.35 | 8.50 | 8.31 |
实施例4水凝胶的抑菌活性测试
大肠杆菌和金黄色葡萄球菌菌液配制：用LB液体培养基分别复苏、传代大肠杆菌和金黄色葡萄球菌，用接种环将细菌均匀分散在装有PBS缓冲溶液的离心管中，置于摇床中恒温振荡培养后得到OD600为0.5的细菌悬浮液。实验所用的玻璃仪器，培养基，PBS缓冲液等实验用品均用高压灭菌锅灭菌，水凝胶样品通过紫外消毒杀菌。
抑菌圈法：将直径为9mm、高度为1mm的圆柱形水凝胶样品分别放入涂有金黄色葡萄球菌和大肠杆菌细菌悬浮液的固体培养基中。所有样品在37℃恒温生化培养箱中培养24h，最后测量抑菌圈大小。每个样本的抑制率（PI）标准如下：PI=di/dh×100%；其中di和dh分别表示抑菌区直径（mm）和水凝胶直径。
表3
| 样品 | 水凝胶1 | 水凝胶2 | 水凝胶3 | 水凝胶4 | 水凝胶5 | 水凝胶6 | 水凝胶7 | 水凝胶8 |
| 金黄色葡萄球菌抑制率 | 87% | 90% | 101% | 106% | 125% | 162% | 166% | 150% |
| 大肠杆菌抑制率 | 95% | 97% | 113% | 117% | 131% | 178% | 173% | 154% |
从表3的实验数据可以发现，本发明的水凝胶采用乙酰化党参多糖和多巴胺共混交联后的抗菌性能大大提升，金黄色葡萄球菌抑制率达到162-166%，大肠杆菌抑制率达到了173-178%，未远高于未加多巴胺的水凝胶，且通过数据可以发现采用天然交联剂也能够一定程度上提高水凝胶的抗菌性能，且当京尼平和柠檬酸混合使用时的抑制率较高。
以上为对本发明实施例的描述，通过对所公开的实施例的上述说明，使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的。本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下，在其它实施例中实现。因此，本发明将不会被限制于本文所示的这些实施列，而是要符合与本文所公开的原理和新颖点相一致的最宽的范围。
Claims (10)
1.一种用于促进伤口愈合的水凝胶，其特征在于，该水凝胶的原料组分包含改性党参多糖。
2.根据权利要求1所述的水凝胶，其特征在于，所述改性党参多糖是乙酰化党参多糖。
3.根据权利要求2所述的水凝胶，其特征在于，所述乙酰化党参多糖采用的乙酰化改性剂为冰醋酸或乙酸酐中的一种。
4.根据权利要求1所述的水凝胶，其特征在于，所述水凝胶的原料组分还包含多巴胺和交联剂。
5.根据权利要求4所述的水凝胶，其特征在于，所述交联剂为京尼平和柠檬酸中的一种或多种组合。
6.权利要求1-5任意一项权利要求所述的水凝胶的制备方法，其特征在于，所述方法包括以下步骤：
1）乙酰化党参多糖的制备：将党参多糖用去离子水充分溶解，加入乙酰化改性试剂，用NaOH溶液控制体系pH8.0-10.0，搅拌反应1-2h，用HCl溶液调节pH至中性，终止反应后透析36-48h，透析液旋转蒸发仪中减压浓缩后加入无水乙醇，4℃醇沉24-48h，冷冻干燥后得乙酰化党参多糖；
2）将步骤1）得到的乙酰化党参多糖加入去离子水中，加热搅拌至溶解，得到乙酰化党参多糖水溶液，加入交联剂水溶液混合，室温下搅拌均匀后静置，然后加入多巴胺水溶液，加热搅拌均匀后静置得到水凝胶。
7.根据权力要求6所述的制备方法，其特征在于，所述乙酰化党参多糖水溶液的质量浓度为5 wt%-10 wt%。
8.根据权利要求6所述的制备方法，其特征在于，所述多巴胺水溶液的质量浓度为1wt%-8 wt%。
9.根据权利要求6所述的制备方法，其特征在于，所述交联剂水溶液的质量浓度为1wt%-2 wt%。
10.权利要求1-5任意一项权利要求所述的水凝胶和权利要求6-9任意一项权利要求所述的制备方法在医用敷料中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210517870.0A CN115010958A (zh) | 2022-05-13 | 2022-05-13 | 一种用于促进伤口愈合的水凝胶及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210517870.0A CN115010958A (zh) | 2022-05-13 | 2022-05-13 | 一种用于促进伤口愈合的水凝胶及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115010958A true CN115010958A (zh) | 2022-09-06 |
Family
ID=83069939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210517870.0A Pending CN115010958A (zh) | 2022-05-13 | 2022-05-13 | 一种用于促进伤口愈合的水凝胶及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115010958A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117143264A (zh) * | 2023-10-30 | 2023-12-01 | 中国医学科学院药用植物研究所 | 乙酰乙酰化黄芪多糖、制备方法及在制备促进伤口愈合水凝胶中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104479150A (zh) * | 2014-10-29 | 2015-04-01 | 上海大学 | 多重交联多糖可注射型水凝胶制备方法 |
| CN109180970A (zh) * | 2018-08-30 | 2019-01-11 | 武汉理工大学 | 一种柠檬酸交联壳聚糖和多巴胺的水凝胶及其制备方法 |
| CN109758675A (zh) * | 2019-01-29 | 2019-05-17 | 青岛中腾生物技术有限公司 | 一种自愈合医用凝胶 |
| CN114129767A (zh) * | 2021-09-09 | 2022-03-04 | 戴钲昊 | 表面封闭性软组织创面保护胶及其应用 |
-
2022
- 2022-05-13 CN CN202210517870.0A patent/CN115010958A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104479150A (zh) * | 2014-10-29 | 2015-04-01 | 上海大学 | 多重交联多糖可注射型水凝胶制备方法 |
| CN109180970A (zh) * | 2018-08-30 | 2019-01-11 | 武汉理工大学 | 一种柠檬酸交联壳聚糖和多巴胺的水凝胶及其制备方法 |
| CN109758675A (zh) * | 2019-01-29 | 2019-05-17 | 青岛中腾生物技术有限公司 | 一种自愈合医用凝胶 |
| CN114129767A (zh) * | 2021-09-09 | 2022-03-04 | 戴钲昊 | 表面封闭性软组织创面保护胶及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| 张吉科等: "山西省"两区"开发农业产业化科技指南", 中国轻工业出版社, pages: 387 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117143264A (zh) * | 2023-10-30 | 2023-12-01 | 中国医学科学院药用植物研究所 | 乙酰乙酰化黄芪多糖、制备方法及在制备促进伤口愈合水凝胶中的应用 |
| CN117143264B (zh) * | 2023-10-30 | 2024-02-20 | 中国医学科学院药用植物研究所 | 乙酰乙酰化黄芪多糖、制备方法及在制备促进伤口愈合水凝胶中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Chitosan membrane dressings toughened by glycerol to load antibacterial drugs for wound healing | |
| Amirian et al. | In-situ crosslinked hydrogel based on amidated pectin/oxidized chitosan as potential wound dressing for skin repairing | |
| Kundu et al. | Cellulose hydrogels: Green and sustainable soft biomaterials | |
| CN110917392B (zh) | 一种具有粘附性的止血抗菌水凝胶及其制备方法 | |
| Kingkaew et al. | Effect of molecular weight of chitosan on antimicrobial properties and tissue compatibility of chitosan-impregnated bacterial cellulose films | |
| CN111150880A (zh) | 一种抗菌复合水凝胶及其制备方法 | |
| Luo et al. | Preparation and characterization of carboxymethyl chitosan sulfate/oxidized konjac glucomannan hydrogels | |
| CN109369948B (zh) | 一种细菌纤维素/聚乙烯醇抗菌水凝胶及其制备方法和应用 | |
| NZ512994A (en) | Process for cross-linking hyaluronic acid to different polymers (other than hyaluronic acid) | |
| CN110152055B (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
| CN111494702B (zh) | 一种抗菌水凝胶及其制备方法与应用 | |
| CN110747534A (zh) | 一种抗菌多糖纤维材料及其制备方法 | |
| CN108484936B (zh) | 一种接枝改性材料所制备的水凝胶及其制备方法和应用 | |
| CN110665050A (zh) | 一种生物粘合剂及其制备方法 | |
| CN112876694B (zh) | 丙烯酸/ε-聚赖氨酸黏附性抗菌水凝胶的制备方法及其应用 | |
| CN111166931A (zh) | 一种甲基丙烯酸丝胶/壳聚糖季铵盐水凝胶及其制备方法和应用 | |
| JPH04275346A (ja) | キトサンを含有している相容性配合物 | |
| Eldin et al. | Chitosan modified membranes for wound dressing applications: Preparations, characterization and bio-evaluation | |
| CN114392388A (zh) | 一种水凝胶组合物及其应用 | |
| CN115010958A (zh) | 一种用于促进伤口愈合的水凝胶及其制备方法和应用 | |
| CN113813396B (zh) | 一种卡那霉素接枝的纤维素基抗菌材料及其制备方法 | |
| Rizwan et al. | Novel chitosan derivative based composite scaffolds with enhanced angiogenesis; potential candidates for healing chronic non-healing wounds | |
| Zhang et al. | Development and characteristic of bacterial cellulose for antimicrobial wound dressing | |
| CN1168766C (zh) | 高强度抗菌性双醛淀粉交联壳聚糖膜及其制法和用途 | |
| Haima et al. | Synthesis and characterisation of glutaraldehyde cross-linked κ-carrageenan-gelatin hydrogel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220906 |
|
| RJ01 | Rejection of invention patent application after publication |